Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium: a case report

Cyril Pottier, Evadnie Rampersaud, Matt Baker, Gang Wu, Joanne Wuu, Jacob L. McCauley, Stephan Zuchner, Rebecca Schule, Christin Bermudez, Sumaira Hussain, Anne Cooley, Marielle Wallace, Jinghui Zhang, J. Paul Taylor, Michael Benatar, Rosa Rademakers

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Homozygous loss-of-function mutations in optineurin (OPTN) are a rare cause of amyotrophic lateral sclerosis (ALS), whereas heterozygous loss-of-function mutations have been suggested to increase ALS disease risk. We report a patient with ALS and frontotemporal dementia (FTD) from the Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium carrying compound heterozygous loss-of-function variants in OPTN. Quantitative real-time mRNA expression analyses revealed a 75–80% reduction in OPTN expression in blood in the OPTN carrier as compared to controls, suggesting at least partial nonsense-mediated decay of the mutant transcripts. This case report illustrates the diverse inheritance patterns and variable clinical presentations associated with OPTN mutations, and underscores the importance of complete OPTN gene screening in patients with ALS and related disorders, especially in the context of clinical genetic testing.

Original languageEnglish (US)
Pages (from-to)469-471
Number of pages3
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume19
Issue number5-6
DOIs
StatePublished - Jul 3 2018

Keywords

  • Amyotrophic lateral sclerosis
  • compound heterozygous
  • frontotemporal dementia
  • mutation
  • optineurin

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium: a case report'. Together they form a unique fingerprint.

  • Cite this